Trastuzumab cardiotoxicity
HER2 drugs can weaken the heart's pumping, usually reversibly, so heart function is checked every three months during treatment.
Asymptomatic LVEF decline in 10-15% and symptomatic heart failure in 1-4% with trastuzumab, higher with prior or concurrent anthracyclines (NSABP B-31: 4.1% vs 0.8%). Mechanism: HER2 signalling maintains cardiomyocyte survival under stress. Management: hold for LVEF drop ≥16 points or below normal, ACE inhibitors/beta-blockers, rechallenge after recovery; anthracycline-free regimens (TCHP, T-DXd neoadjuvant) reduce risk.
Pages like this
not linked directly; found by shared links- IdeaA risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy
Shares Cardio-oncology, Survivorship and late effects are neglected, Trastuzumab, HER2-positive breast cancer.
- IdeaBiomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy
Shares Cardio-oncology, Survivorship and late effects are neglected, Trastuzumab, HER2-positive breast cancer.
- PersonAndrew Wardley
Shares PERSEPHONE, Trastuzumab, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- PairingEarly FDG-PET response → chemotherapy omission (HER2+)
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
- IdeaRisk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care
Shares Cardio-oncology, Survivorship and late effects are neglected.
- IdeaA survivor biobank to find who will develop late effects before they do
Shares Cardio-oncology, Survivorship and late effects are neglected.
- TrialAPHINITY
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.